Ouabain-like factor

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 2, 1998, Pages 189-196

  Goto, Atsuo ^a   Yamada, Kaoru ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Sanraku Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE INHIBITOR; BUFADIENOLIDE; BUFALIN; BUFOGENIN; CARDENOLIDE; DEOXYCORTICOSTERONE ACETATE; DIGITALIS LIKE FACTOR; DIGOXIN ANTIBODY F(AB) FRAGMENT; MINERALOCORTICOID; PROSCILLARIDIN; PROTON PUMP INHIBITOR; SODIUM;

ARTICLE; BLOOD PRESSURE; CALCIUM TRANSPORT; DIURETIC ACTIVITY; ESSENTIAL HYPERTENSION; HUMAN; HYPERVOLEMIA; MATERNAL HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SODIUM BALANCE; SODIUM INTAKE;

ANIMALS; BIOLOGICAL FACTORS; BLOOD PRESSURE; CARDENOLIDES; DIGOXIN; ENZYME INHIBITORS; HUMANS; HYPERTENSION; NA(+)-K(+)-EXCHANGING ATPASE; NATRIURESIS; SAPONINS;

EID: 0031883698     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199803000-00008     Document Type: Article

References (64)

1. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int 1996; 49:1748-1753.
2. Hamlyn JM, Hamilton BP, Manunta P. Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J Hypertens 1996: 14:151-167.
3. de Wardener HE. Sodium transport inhibitors and hypertension. J Hypertens 1996; 14 (Suppl 5):S9-S18.
4. de Wardener HE. Ouabain and hypertension. Nephrol Dial Transplant 1997; 12:384-385.
5. Doris PA. Endogenous inhibitors of the Na,K pump. Miner Electrolyte Metab 1996; 22:303-310. A thoughtful review suggesting that chemical properties including its high polarity may make OLF an inadequate candidate for an endogenous sodium pump inhibitor.
6. Hollenberg NK, Graves SW. Endogenous sodium pump inhibition: current status and therapeutic opportunities. Prog Drug Res 1996; 46:9-42. A thoughtful review emphasizing the application of Koch's postulates in the field of endogenous sodium pump inhibitor.
7. Balzan S, Montali U, Di Bartolo V, Ghione S. Further evidence for an endogenous digitalis-like compound in newborn and adult plasma detected by anti-ouabain antiserum. Life Sci 1997; 60:893-898. This study definitely demonstrates the presence of OLF in human plasma.
8. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P, et al. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30: 886-896. A systematic work documenting the existence of OLF in human plasma and rat plasma and tissues. This study points out that the differences in sample preparation as well as in antibodies may markedly affect the detectability of OLF and its concentrations.
9. Harwood S, Little JA, Gallacher G, Perrett D, Edwards R, Dawnay A. Development of enzyme immunoassay for endogenous ouabain-like compound in human plasma. Clin Chem 1997; 43:715-722.
10. Worgall S, Hanze J, Wagner R, Peiser C, Lang RE, Sulyok E, Rascher W. Characterization of ouabain-like immunoreactivity in human urine. J Hypertens 1996; 14:623-628.
11. Paci A, Ciarimboli G, Biver P. Human placental radioreceptor assay with digoxin and ouabain to detect endogenous digitalis-like factor(s) in human plasma and urine. Clin Chem 1996; 42:270-278.
12. Qazzaz HMA, Jortani SA, Poole JM, Valdes R Jr. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (dihydro-DLIF) in mammalian tissues. Clin Chem 1996; 271:8731-8737. This study suggests a metabolic route for the synthesis of endogenous DLF in mammalian tissue.
13. Qazzaz HMA, Goudy SL, Valdes R Jr. Deglycosylated products of endogenous digoxinlike immunoreactive factor in mammalian tissue. J Biol Chem 1996; 271:8731-8737.
14. Chasalow Fl. Structure of mammalian cardenolide conjugates (endogenous digoxin-like materials). Program and Abstracts for the 79th Annual Meeting of the American Endocrine Society 1997; 256.
15. De Angelis C, Riscazzi M, Salvini R, Piccoli A, Ferri C, Santucci A. Isolation and characterization of a digoxin-like immunoreactive substance from human urine by affinity chromatography. Clin Chem 1997; 43:1416-1420.
16. Weinberg U, Dolev S, Shapiro MS, Shilo L, Rabinowitz R, Shenkman L. Digoxinlike immunoreactive factor isolated from human pleural fluids is structurally similar to digoxin. Am J Med Sci 1997; 314:28-30.
17. +-ATPase activity in bovine lens. Pflugers Arch Eur J Physiol 1997; 433:435-441.
18. Hilton PJ, Wright DA, Lord GA, Garner GV, Gordon DB, Hilton MJ, et al. An inhibitor of the sodium pump obtained from human placenta. Lancet 1996; 348:303-305.
19. Wright DA, Lord GA, White RW, Hilton MJ, Gordon DB, Hilton PJ. Evidence for circulating bufenolide in a volume-expanded patient. Lancet 1997; 350:409.
20. Bagrov AY, Dmitrieva RI, Fedorova OV, Kazakov GP, Roukoyatkina NI, Shpen VM. Endogenous marinobufagenin-like immunoreactive substance: a possible endogenous Na,K-ATPase inhibitor with vasoconstrictor activity. Am J Hypertens 1996; 9:982-990.
21. Sich B, Kirch U, Tepel M, Zidek W, Schoner W. Pulse pressure correlates in humans with a procillaridin A immunoreactive compound. Hypertension 1996; 27:1073-1078.
22. Tao Q-F, Soszynski PA, Hollenberg NK, Graves SW. Specificity of the volume-sensitive sodium pump inhibitor isolated from human peritoneal dialysate in chronic renal failure. Kidney Int 1996; 49:420-429.
23. Tao Q-F, Hollenberg NK, Price AP, Graves SW. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate. Hypertension 1996; 29:815-821. This study demonstrates clearly that the effects of endogenous sodium pump inhibitor on α isoforms are different from those of ouabain.
24. Qazzaz HMA, Valdes R Jr. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues. Arch Biochem Biophys 1996; 328:193-200.
25. Butler VP Jr, Morris JF, Akizawa T, Matsukawa M, Keating M, Hardart A, Furman I. Heterogeneity and lability of endogenous digitalis-like substances in the plasma of the toad, Bufo marinus. Am J Physiol 1996; 271:R325-R332. This study provides evidence of the enzyme conjugating and decon-jugating bufodienolide in toad plasma. This finding may be applicable to mammals.
26. Fedorova OV, Bagrov AY. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different α-subunit isoforms. Am J Hypertens 1997; 10:929-935. This paper suggests one of the possible reasons why different sodium pump inhibitors do exist in mammals.
27. Laredo J, Shah JR, Lu Z-R. Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension 1997; 29:401-407.
28. Perrin A, Brasmes B, Chambaz EM, Defaye G. Bovine adrenocortical cells in culture synthesize an ouabain-like compound. Mol Cell Endocrinol 1997; 126:7-15. This paper independently confirms the claim of Laredo et al. (see [27]) that adrenocortical cells synthesize and release OLF.
29. Doris PA, Hayward-Lester A, Bourne D, Stocco DM. Ouabain production by cultured adrenal cells. Endocrinology 1996; 137:533-539.
30. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996; 272:676-680.
31. Woolfson RG, de Wardener HE. Primary renal abnormalities in hereditary hypertension. Kidney Int 1996; 50:717-731.
32. Cusi D, Bartassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349:1353-1357.
33. Pidgeon GB, Richards AM, Nichols MG, Chartes CJ, Rademaker MT, Lynn KI, et al. Chronic ouabain infusion does not cause hypertension in sheep. Am J Physiol 1996; 270:E386-E392.
34. Fedorova OV, French AW, Anderson DE. Inhibition of erythrocyte Na,K-ATPase activity during anticipatory hypoventilation in micropigs. Am J Hypertens 1996; 9:1126-1131.
35. Zhu Z, Tepel M, Neusser M, Zidek W. Low concentrations of ouabain increase cytosolic free calcium concentration in rat vascular smooth muscle cells. Clin Sci 1996; 90:9-12.
36. 2+.
37. + pump a subunit isoforms in plasmalemma. Physiological implications. Ann NY Acad Sci 1997; in press.
38. Goto A, Yamada K, Hazama H, Uehara Y, Atarashi K, Hirata Y, et al. Ouabain-like compound in hypertension associated with ectopic corticotrophin syndrome. Hypertension 1996; 28:421-425.
39. Yamada K, Goto A, Omata M. Adrenocoticotropin-induced hypertension in rats: role of ouabain-like compound. Am J Hypertens 1997; 10:403-408.
40. Weiler EWJ, Saldanha LF, Khalilmanesh F, Prins BA, Purdy RE, Gonick HC. Relationship of Na K ATPase inhibitors to blood pressure regulation in continuous ambulatory peritoneal dialysis and hemodialysis. J Am Soc Nephrol 1996; 7:454-463.
41. +-ATPase obtained from human placenta. Mol Cell Biochem 1997; 170:125-129.
42. Li M, Wen C, Whitworth JA. Hemodynamic effects of the Fab fragment of digoxin antibody (Digibind) in corticotropin (ACTH)-induced hypertension. Am J Hypertens 1997; 10:332-336.
43. Adair CD, Buckalew V, Taylor K, Ernest JM, Frye AH, Evans C, Veille J. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol 1996; 16:529-531.
44. Huang BS, Leenen F. Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANGII. Am J Physiol 1996; 270:H272-H280.
45. Huang BS, Leenen F. Brain 'ouabain' and angiotensin II in salt-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1996; 28:1005-1012.
46. Veerasingham SJ, Leenen F. Excitotoxic lesions of the ventral anteroventral third ventricle and pressor responses to central sodium, ouabain and angiotensin II. Brain Res 1997; 749:157-160.
47. Budzikowski AS, Leenen F, Brain 'ouabain' in the median preoptic nucleus mediates sodium-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1997; 29:599-605.
48. Teruya H, Yamazato M, Muratani H, Sakima A, Takishita S, Terano Y, Fukiyama K. Role of ouabain-like compound in the rostral ventrolateral medulla in rats. J Clin Invest 1997; 99:2791-2798.
49. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, et al. 17β-(3-furyl)-5β-androstane-3β,14αtriol(PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem 1997; 40:1561-1564. A first report on the antihypertensive effects of an anti-OLF agent.
50. Kantoci D, Wechter WJ, Murray ED Jr, Dewind SA, Borchardt D, Khan Sl. Endogenous natriuretic factors 6: the stereochemistry of a natriuretic γ-tocopherol metabolite LLU-α. J Pharmacol Exp Ther 1997; 282:648-656.
51. Murray ED Jr, Wechter WJ, Kantoci D, Wang W-H, Pham T, Quiggle DD, et al. Endogenous natriuretic factors 7: biospecificity of a natriuretic γ-tocopherol metabolite LLU-α. J Pharmacol Exp Ther 1997; 282:657-662.
52. Kurashina T, Kirchner KA, Granger JP, Patel AR. Chronic sodium-potassium-ATPase inhibition with ouabain impairs renal hemodynamics and pressure natriuresis in the rat. Clin Sci 1996; 91:497-502.
53. Pamnani MB, Mo Z, Chen S, Bryant HJ, White RJ, Haddy FJ. Effects of head-down tilt on hemodynamics, fluid volumes, and plasma Na-K pump inhibitor in rats. Avia Space Environ Med 1996; 67:928-934.
54. Serma Y, Butt AN, Swaminathan R, Effect of salt intake on excretion of endogenous ouabain-like substance, measured by RIA. Clin Chem 1996; 42:1949-1954.
55. Butt AN, Serma YK, Ho CS, Swaminathan R, Effect of high satl intake on plasma and tissue concentration of endogenous ouabain-like substance in the rat. Life Sci 1997; in press.
56. Ho CS, Butt AN, Serma YK, Swaminathan R, Effect of carbidopa on the excretion of sodium, dopamine and ouabain-like substance in the rat. Hypertension 1997; 30:1544-1548.
57. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, Anderson DE, Plasma marinobufagenin-like and ouabain-like immunoreactivity during acute saline volume expansion in anesthetized dogs. Cardiovasc Res 1996; 206:296-305.
58. Yates NA, MCDougall JG, Interaction of exogenous ouabain and chronic mineralocorticoid treatment in the kidney of the conscious sheep. Clin Exp Pharmacol Physiol 1997; 24:57-63. This study demonstrates that aldosterone potentiates a natriuretic effect of ouabain as well as its pressor action.
59. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab 1996; 81:2335-2337.
60. Tamura M, Piston DW, Tani M, Naruse M, Jandon EJ, Inagami T. Ouabain increases aldosterone release from bovine adrenal glomerulosa cells; role of renin-angiotensin system. Am J Physiol 1996; 270:E27-E35.
61. Gilson GJ, Graves SW, Quails CR, Curet LB. Digoxin-like immunoreactive substance and sodium-potassium-adenosine triphosphatase inhibition in normal pregnancy: a longitudinal study. Obstet Gynecol 1997; 89:743-746.
62. Arnason SS, Vakkuri O, Vuolteeaho O, Pouta A, Leppaluto J. Ouabain in human placenta and in plasma during pregnancy. Hypertension 1997; 30:494.
63. Yamada K, Goto A, Nagoshi H, Terano Y, Omata M. Elevation of ouabain-like compound levels with hypertonic sodium chloride load in rat plasma and tissue. Hypertension 1997; 30:94-98.
64. Goto A, Yamada K, Nagoshi H, Dan Y, Omata M. Role of ouabain-like compound in the regulation of transmembrane sodium and potassium gradients in rats. Hypertension 1997; 30:753-758. This study suggests the possibility that OLF may be one of the regulators of plasma sodium or potassium concentrations.